SecBot SecBot
8-K ·Filed Apr 10, 2026

SLDB

Solid Biosciences Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago SEC0001193125-26-151259
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine corporate governance adjustment with no operational or strategic implications. Traders should not expect stock movement based on this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.39
T+0 close · Apr 10, 2026 · via day close
Latest settled
+31.11%
T+60 · $11.00
Vs SPY
+22.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $8.39entry
  2. T+1 · 7mo ago −1.91%α −3.12% · $8.23
  3. T+5 · 7mo ago +1.19%α −2.10% · $8.49
  4. T+20 · 6mo ago −8.46%α −16.19% · $7.68
  5. T+60 · 4mo ago +31.11%α +22.19% · $11.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned from Class III and was immediately reappointed to Class I to balance board composition. The move is procedural and does not reflect a change in leadership or strategy.

Key Facts

  • Ilan Ganot resigned from Class III of the Board and was reappointed to Class I effective April 10, 2026
  • The change was made to achieve equal balance among the three board classes
  • No changes to Ganot's compensation or role responsibilities were made
  • Stockholders will be asked to ratify the appointment on an advisory basis at the 2026 Annual Meeting

Financial Impact

No financial impact

compensationboard structure

Risk Factors

  • Advisory ratification at the 2026 Annual Meeting could face shareholder opposition, though unlikely given the procedural nature

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-151259
Document: 0001193125-26-151259-index-headers.html0001193125-26-151259
Document: 0001193125-26-151259-index.html0001193125-26-151259
Document: 0001193125-26-151259.txt0001193125-26-151259

Track record

14 reports on SLDB

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
  3. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
  4. Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
  5. May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
  6. May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
  7. Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
  8. Apr 10, 202631w ago 8-K Neutral 2/10 Viewing Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
  9. Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
  10. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026